Novo Nordisk’s Semaglutide Tops Madrigal’s Rezdiffra In NASH

Greater Combined Effect Seen In Phase III Trials

 
• By Joseph Haas
  
Novo Nordisk presented more data for semaglutide in NASH at AASLD (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Conferences

More from Alimentary/Metabolic